keyword
https://read.qxmd.com/read/38645297/dalbavancin-as-an-alternative-to-traditional-outpatient-parenteral-antimicrobial-therapy-for-deep-gram-positive-infections-an-observational-retrospective-review
#1
JOURNAL ARTICLE
Hongkai Bao, Rita Igwilo-Alaneme, Fnu Sonia, Kelsie Cowman, Mani Kahn, Priya Nori
BACKGROUND: Treatment of invasive gram-positive infections in complex patient populations is challenging. Dalbavancin, approved for skin and soft tissue infections, offers advantages in this setting due to its long half-life and infrequent dosing. However, less is known about the outcomes of off-label dalbavancin for deeper infections. OBJECTIVES: The objective of this study is to examine the feasibility and outcomes of patients with complex gram-positive infections treated with dalbavancin as an alternative to standard outpatient parenteral antimicrobial therapy (OPAT)...
2024: Therapeutic Advances in Infectious Disease
https://read.qxmd.com/read/38643831/outpatient-parenteral-antibiotic-treatment-for-infective-endocarditis-a-retrospective-observational-evaluation
#2
JOURNAL ARTICLE
Dr Ralph Schwiebert, Dr Sokolayam Atanze, Dr Uchechika Iroegbu, Dr Molly Wilkins, Jonathan A T Sandoe
BACKGROUND: Infective endocarditis (IE) requires long courses of intravenous (IV) antibiotics. Outpatient parenteral antibiotic therapy (OPAT) saves resources, improves the patient experience and allows care in their preferred place; however, questions remain about safety when treating IE patients. This study evaluates OPAT management of IE patients in our region between 2006 and 2019. METHODS: This is a retrospective observational evaluation and description of outcomes and adherence to suitability criteria, according to British Society for Antimicrobial Chemotherapy (BSAC) guidelines...
April 19, 2024: Clinical Medicine: Journal of the Royal College of Physicians of London
https://read.qxmd.com/read/38633125/poor-outcomes-for-trial-ineligible-patients-receiving-polatuzumab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-routine-care-an-australian-lymphoma-and-related-diseases-registry-project
#3
JOURNAL ARTICLE
Briony Shaw, Eliza Chung, Cameron Wellard, Edward Yoo, Rory Bennett, Callum Birks, Anna Johnston, Chan Y Cheah, Nada Hamad, Jock Simpson, Allison Barraclough, Matthew Ku, Nicholas Viiala, Sumita Ratnasingam, Tasman Armytage, Tara Cochrane, Geoffrey Chong, Denise Lee, Kate Manos, Colm Keane, Stephanie Wallwork, Stephen Opat, Eliza A Hawkes
Polatuzumab vedotin (Pola) is an approved therapy in combination with rituximab and bendamustine for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL) based on positive results of the landmark phase II randomised G029365 trial. However, trial results for many approved novel therapies in RR-DLBCL have not been replicated in routine care cohorts, as RR-DLBCL patient populations are heterogeneous and trial eligibility is increasingly restrictive. We evaluated outcomes from pola ± bendamustine and rituximab in patients with RR-DLBCL enrolled in a compassionate access program with no alternative treatment options identified via the Australasian Lymphoma and Related Diseases Registry according to their eligibility for the original phase II published study...
April 2024: EJHaem
https://read.qxmd.com/read/38623842/the-authors-reply-to-jensen-et-al-s-letter-to-the-editor
#4
JOURNAL ARTICLE
Christina M Kaul, Matthew Haller, Jenny Yang, Sadie Solomon, Maria R Khan, Robert A Pitts, Michael S Phillips
No abstract text is available yet for this article.
April 16, 2024: Infection Control and Hospital Epidemiology
https://read.qxmd.com/read/38591847/home-nursing-and-self-administered-outpatient-parenteral-antimicrobial-treatment-a-comparison-of-demographics-and-outcomes-from-a-large-regional-hospital-in-queensland-australia
#5
JOURNAL ARTICLE
Holly Brand, Michael Fryer, Ahmed M Mehdi, Alex Melon, Bridie Morcombe, Keat Choong, Shradha Subedi
BACKGROUND: Outpatient parenteral antimicrobial treatment (OPAT) is a safe and effective therapy used in several settings across Australia. As OPAT services expand their inclusion criteria to include complex patient populations, there is an increased need for selecting appropriate patients to receive either healthcare-administered OPAT (H-OPAT) or self-administered OPAT (S-OPAT). AIMS: To describe patient demographics, diagnosis, microbiology and outcomes of patients treated by H-OPAT and S-OPAT within the Sunshine Coast Hospital and Health Service, Australia...
April 9, 2024: Internal Medicine Journal
https://read.qxmd.com/read/38585225/evaluation-of-the-stability-of-ceftazidime-avibactam-in-elastomeric-infusion-devices-used-for-outpatient-parenteral-antimicrobial-therapy-utilizing-a-national-stability-protocol-framework
#6
JOURNAL ARTICLE
Saiyuri Naicker, Jason A Roberts, Hayoung Won, Steven C Wallis, Sean Unwin, Conor Jamieson, Tim Hills, Mark Gilchrist, Mark Santillo, R Andrew Seaton, Felicity Drummond, Fekade B Sime
OBJECTIVES: To evaluate the stability of ceftazidime/avibactam in elastomeric infusers, utilizing the UK's Yellow Cover Document (YCD) stability testing framework, in conditions representative of OPAT practice. METHODS: Ceftazidime/avibactam was reconstituted with sodium chloride 0.9% (w/v) in two elastomeric infusers at concentrations (dose) levels of 1500/375, 3000/750 and 6000 mg/1500 mg in 240 mL. The infusers were exposed to a fridge storage (2°C-8°C) for 14 days followed by 24 h in-use temperature (32°C)...
April 2024: JAC-antimicrobial resistance
https://read.qxmd.com/read/38569764/strategies-to-improve-patient-centered-care-for-drug-use-associated-infective%C3%A2-endocarditis-jacc-focus-seminar-2-4
#7
REVIEW
Alysse G Wurcel, Joji Suzuki, Asher J Schranz, Ellen F Eaton, Nicolas Cortes-Penfield, Larry M Baddour
Drug use-associated infective endocarditis (DUA-IE) is a major cause of illness and death for people with substance use disorder (SUD). Investigations to date have largely focused on advancing the care of patients with DUA-IE and included drug use disorder treatment, decisions about surgery, and choice of antibiotics during the period of hospitalization. Transitions from hospital to outpatient care are relatively unstudied and frequently a key factor of uncontrolled infection, continued substance use, and death...
April 9, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38513178/expanding-research-on-firefighter-trainee-fitness-reasons-for-academy-release-and-the-predictive-capabilities-of-fitness-tests
#8
JOURNAL ARTICLE
Robert G Lockie, Robin M Orr, Fernando Montes, J Jay Dawes
Lockie, RG, Orr, RM, Montes, F, and Dawes, JJ. Expanding research on firefighter trainee fitness, reasons for academy release, and the predictive capabilities of fitness tests. J Strength Cond Res 38(4): 724-733, 2024-Firefighter trainees need a level of fitness to be admitted to and complete a training academy. Fitness could indicate a trainee's likelihood of graduation, in addition to their reasons for release. This study determined fitness differences between firefighter trainees who graduated (GRAD) from academy or were released because of injury (RELI), performance test failures (RELP), or resignation (RELR), and whether fitness predicted graduation...
April 1, 2024: Journal of Strength and Conditioning Research
https://read.qxmd.com/read/38511820/evaluation-of-health-related-quality-of-life-in-patients-receiving-outpatient-parenteral-antimicrobial-therapy-opat-in-a-uk-setting
#9
JOURNAL ARTICLE
Oyewole Christopher Durojaiye, Evangelos I Kritsotakis
BACKGROUND: Studies assessing the benefits of outpatient parenteral antimicrobial therapy (OPAT) have paid less attention to patient-centered factors such as patients' experiences and their health-related quality of life (HRQoL). RESEARCH DESIGN AND METHODS: Prospective before-and-after quasi-experimental study enrolled adult patients receiving OPAT at a tertiary hospital in Derbyshire, UK, between October 2022 and October 2023. Consenting patients completed paired EQ-5D-3 L questionnaires before OPAT initiation and upon completion of therapy or 30 days after its commencement (whichever occurred first)...
March 21, 2024: Expert Review of Anti-infective Therapy
https://read.qxmd.com/read/38489600/exploring-the-impact-of-firefighter-trainee-fitness-on-academy-graduation-or-release
#10
JOURNAL ARTICLE
Robert G Lockie, Robin M Orr, Fernando Montes, J Jay Dawes
Lockie, RG, Orr, RM, Montes, F, and Dawes, JJ. A research note exploring the impact of firefighter trainee fitness on academy graduation or release. J Strength Cond Res XX(X): 000-000, 2024-This study investigated the impact of fitness test performance on firefighter trainee ability to graduate an academy using ordinal logistic generalized linear models. Retrospective analysis was conducted on trainee data (N = 686) from one fire department who completed an occupational physical ability test (OPAT) that included the following: Illinois agility test (IAT); push-ups; pull-ups; leg tucks; maximal aerobic capacity (V̇o2max); backward overhead 4...
March 14, 2024: Journal of Strength and Conditioning Research
https://read.qxmd.com/read/38489567/chronic-lymphocytic-leukemia-time-to-care-for-the-survivors
#11
JOURNAL ARTICLE
Pasquale L Fedele, Stephen Opat
No abstract text is available yet for this article.
March 15, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38481906/dalbavancin-as-a-viable-alternative-for-addressing-treatment-adherence-in-methicillin-resistant-staphylococcus-aureus-mrsa-bacteremia-a-case-report
#12
Michael Sabina, Jessica Cobian, Imad Dibo
Outpatient parenteral antibiotic therapy (OPAT) aims to facilitate antibiotic treatment in non-hospital settings while minimizing hospitalization costs and infection risks. However, ensuring patient adherence, especially among socially disadvantaged groups like the homeless may be challenging. Studies indicate that increased dosing frequency negatively impacts adherence rates. Simplified dosing schedules and addressing transportation barriers are protective measures. Dalbavancin, a weekly oral antibiotic with an extended half-life, may offer a solution for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in patients with adherence challenges...
February 2024: Curēus
https://read.qxmd.com/read/38478255/outpatient-parenteral-antimicrobial-therapy-opat-in-germany-insights-and-clinical-outcomes-from-the-k-apat-cohort-study
#13
JOURNAL ARTICLE
Kirsten Schmidt-Hellerau, Nina Baade, Marina Günther, Nadine Scholten, Christoph Heinrich Lindemann, Charlotte Leisse, Charlotte Oberröhrmann, Sophie Peter, Norma Jung, Isabelle Suarez, Carola Horn, Peter Ihle, Jutta Küpper-Nybelen, Anna Hagemeier, Martin Hellmich, Clara Lehmann
PURPOSE: Outpatient parenteral antimicrobial therapy (OPAT) offers several key advantages, including enhanced patient quality of life, reduced healthcare costs, and a potential reduction of nosocomial infections. It is acknowledged for its safety and effectiveness. This study provides the first systematic clinical data for Germany, where OPAT has not yet been widely adopted. The aim is to establish a foundational reference point for further research and integration of OPAT into the German healthcare system...
March 13, 2024: Infection
https://read.qxmd.com/read/38450504/impact-and-utility-of-follicular-lymphoma-gelf-criteria-in-routine-care-an-australasian-lymphoma-alliance-study
#14
JOURNAL ARTICLE
Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, Geoffrey Chong, Edward Yoo, Chan Y Cheah, Nunzio Franco, Bianca Nguyen, Howard Mutsando, Fatima Tahir, Judith Trotman, Jing Huang, Colm Keane, Mitchel Lincoln, Tara Cochrane, Anna M Johnston, Michael Dickinson, Stephen Opat, Zoe K McQuilten, Erica M Wood, Gayathri St George, Eliza A Hawkes
Follicular Lymphoma (FL) treatment initiation is largely determined by tumor burden and symptoms. In the pre-rituximab era, the Group d'Etude des Lymphomes Folliculaires (GELF) developed widely adopted criteria to identify high tumor burden FL patients to harmonize clinical trial populations. The utilization of GELF criteria (GELFc) in routine therapeutic decision-making is poorly described. This multicenter retrospective study evaluated patterns of GELFc at presentation and GELFc utilization in therapeutic decision-making in newly diagnosed, advanced stage rituximab-era FL...
March 7, 2024: Haematologica
https://read.qxmd.com/read/38449918/dalba-got-back-use-of-dalbavancin-for-the-treatment-of-vertebral-osteomyelitis
#15
Amber C Streifel, Luke C Strnad, Monica K Sikka, Cara D Varley, Jina Makadia, Ellie Sukerman, Alyse H Douglass, Heather Mayer, Kathleen Young, James S Lewis
Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.
March 2024: Open Forum Infectious Diseases
https://read.qxmd.com/read/38423135/barriers-and-facilitators-for-the-implementation-and-expansion-of-outpatient-parenteral-antimicrobial-therapy-systematic-review
#16
REVIEW
Solomon Ahmed Mohammed, Menino Osbert Cotta, Getnet Mengistu Assefa, Daniel Erku, Fekade Sime
BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) program has been expanding in recent years and serves as a viable solution in reducing the shortage of hospital beds. However, the wider implementation of OPAT faces numerous challenges. This review aimed to assess implementation barriers and facilitators of OPAT services. METHODS: Studies describing barriers and facilitators to OPAT service were retrieved from PubMed, Scopus, MEDLINE, EMBASE, CINAHL, Cochrane Library, Web of Science Proceedings, International Pharmaceutical Abstracts, and PsycINFO...
February 27, 2024: Journal of Hospital Infection
https://read.qxmd.com/read/38421503/improving-antimicrobial-treatment-in-terms-of-antimicrobial-stewardship-and-health-costs-by-an-opat-service
#17
JOURNAL ARTICLE
Andrea R Burch, Bruno Ledergerber, Martin Ringer, Maria Padrutt, Claudine Reiber, Fabienne Mayer, Annelies S Zinkernagel, Nadia Eberhard, Marisa B Kaelin, Barbara Hasse
PURPOSE: Outpatient parenteral antimicrobial therapy (OPAT) is a standard for antimicrobial therapy internationally. With this prospective cohort study, we aimed to assess the impact of an OPAT service as part of antimicrobial stewardship (AMS) and evaluate the safety and efficiency of the program while illuminating the financial benefit for the hospital. METHODS: Socio-demographic data, treatment regimen and outcomes were prospectively recorded for all patients assigned to the program of the OPAT unit of the University Hospital of Zurich between November 2018 and September 2022...
February 29, 2024: Infection
https://read.qxmd.com/read/38412514/creation-and-validation-of-an-automated-registry-for-outpatient-parenteral-antibiotics
#18
COMMENT
Joseph Canterino, Maricar Malinis, Jing Liu, Nitu Kashyap, Cynthia Brandt, Amy Justice
Existing outpatient parenteral antibiotic therapy (OPAT) registries are resource intensive, and OPAT programs struggle to produce objective data to show the value of their work. We describe the building and validation of an automated OPAT registry within our electronic medical record and provide objective data on the value of the program. Variables and outcomes include age, sex, race, ethnicity, primary insurance payor, antibiotic names, infection syndromes treated, discharge disposition, 30-day all-cause readmission and death rates, complications, and an estimate of the hospital days saved...
February 2024: Open Forum Infectious Diseases
https://read.qxmd.com/read/38412509/making-the-ehr-work-for-you-modifications-of-an-electronic-health-record-system-to-improve-tracking-and-management-of-patients-receiving-outpatient-parenteral-antibiotic-therapy
#19
COMMENT
Sonal S Munsiff, Colleen Burgoyne, Erica Dobson, Alexandra Yamshchikov
BACKGROUND: Managing the complex needs of outpatient parenteral antibiotic therapy (OPAT) patients is challenging and time-consuming. We describe development of multimodal interventions to facilitate patient management within an Epic® (Epic Systems Corporation)-based electronic health record (EHR) platform. METHODS: During 2016-2018, a multidisciplinary team created several modifications in our local EHR to improve gaps in OPAT care, including shared note templates, shared patient lists, automatically triggered notifications, and comprehensive order sets...
February 2024: Open Forum Infectious Diseases
https://read.qxmd.com/read/38391538/clinical-effectiveness-of-continuous-infusion-flucloxacillin-in-the-outpatient-parenteral-antimicrobial-therapy-opat-setting-in-a-uk-hospital-a-service-evaluation
#20
JOURNAL ARTICLE
Annette Margaret Clarkson, Susan Snape
The availability of stability data for the use of continuous intravenous flucloxacillin in an elastomeric device has enabled the treatment of serious Methicillin Sensitive Staphylococcus aureus (MSSA) in the outpatient parenteral antimicrobial therapy (OPAT) setting. This service review aimed to evaluate current standard of care to establish the clinical effectiveness and complication rates associated with its use since its introduction at our institution. A retrospective review of clinical outcomes and adverse events/complications, was undertaken for all patients who received continuous infusion flucloxacillin for complicated MSSA infection between January 2019 and July 2022 via our OPAT service...
February 3, 2024: Antibiotics
keyword
keyword
55881
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.